부산대학교 도서관

In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT(HSCT) in 32075 patients (13470 allogeneic (42%), 18605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10113(32%;94% allogeneic);lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18433(57%; 12% allogeneic);solid tumours; 1573(5%;5% allogeneic);and non-malignant disorders; 1830(6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%);proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of > 2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries. Bone Marrow Transplantation (2013) 48, 1161-1167; doi:10.1038/bmt.2013.51; published online 15 April 2013 Keywords: haematopoietic SCT; reduced-intensity conditioning; transplant rates; trends; indications 200 130 3 11 19 128 82 22 595
INTRODUCTION Hematopoietic SCT (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system. (1-4) Forecasts predict an on-going increase in HSCT in the near future. [...]